Get started
Work

Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer

Year: 2021
Type: review
Abstract: Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1-5) transduce signals via intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to negatively regulate immune activation. The activation of LILRB signaling in immune cells may contribute to immune evasion. In addition, the expression and signaling of LILRBs in cancer cells especially in certain hematologic malignant cells directly support cancer development. Certain LILRBs thus have dual roles in cancer biology-as immune checkpoint molecules and tumor-supporting factors. Here, we review the expression, ligands, signaling, and functions of LILRBs, as well as therapeutic development targeting them. LILRBs may represent attractive targets for cancer treatment, and antagonizing LILRB signaling may prove to be effective anti-cancer strategies.
DOI: 10.1093/abt/tbab002
Authors: Mi Deng, Heyu Chen, Xiaoye Liu, Ryan Huang, Yubo He, Byounggyu Yoo, Jingjing Xie, Samuel John, Ningyan Zhang, Zhiqiang An, Cheng Cheng Zhang
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,625
Awards: G1277860013, Therapeutic Monoclonal Antibody Lead Optimization and Development Core, Advanced Cancer Antibody Drug Modalities Core Facility, ITIM-receptors for cancer treatment, Integrative Immunology Training Grant, Fasting-induced inhibition of leukemia development
OpenAlex ID: W3128104165
FWCI: 0.819
Cites: 305
Cited by: 55
Related to: 10